Can You Take Synthroid (Levothyroxine) with Finasteride?

Why This Combination Is Prescribed Together

Levothyroxine replaces deficient thyroid hormone in patients with hypothyroidism, while finasteride inhibits 5-alpha reductase to treat androgenetic alopecia or benign prostatic hyperplasia (BPH). These conditions frequently co-exist, particularly in men over 40.

Prevalence of Co-Prescription

The American Thyroid Association estimates that hypothyroidism prevalence in the U.S. General population is 4.6% when including subclinical disease. Androgenetic alopecia affects approximately 50% of men by age 50, according to epidemiologic data published in the Journal of the American Academy of Dermatology. The statistical overlap means millions of men take both drugs simultaneously.

Clinical Rationale for Concern

Patients and clinicians sometimes ask about this combination because hypothyroidism itself can cause hair thinning and altered androgen metabolism. The worry is that adding finasteride to a thyroid-replacement regimen might mask diagnostic signals or interfere with hormonal balance. The evidence does not support these concerns.

Pharmacokinetic Analysis: No Metabolic Conflict

Levothyroxine (T4) is a prohormone converted to triiodothyronine (T3) by deiodinase enzymes in peripheral tissues. It does not undergo hepatic phase I metabolism through cytochrome P450 enzymes. Its elimination relies on deiodination, glucuronidation, and sulfation in the liver and kidneys.

Finasteride's CYP3A4 Pathway

Finasteride is metabolized primarily by CYP3A4 in the liver. It does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic doses of 1 mg (hair loss) or 5 mg (BPH). Because levothyroxine bypasses the CYP system entirely, no competitive inhibition or enzyme induction scenario exists between these two drugs.

Absorption and P-glycoprotein

Levothyroxine absorption occurs primarily in the jejunum and upper ileum and is highly sensitive to gastric pH, calcium, iron, and certain foods. Finasteride is absorbed in the upper GI tract with approximately 80% bioavailability but does not alter gastric pH, does not chelate minerals, and is not a P-glycoprotein substrate or inhibitor according to its FDA prescribing information. No absorption interference has been documented.

Protein Binding: Theoretical but Not Clinical

Levothyroxine is 99.97% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin. Finasteride is approximately 90% protein-bound, primarily to albumin. Displacement interactions between two highly protein-bound drugs are a textbook concern, but clinically relevant displacement requires competition for the same binding protein at concentrations high enough to shift free drug levels. No case report, pharmacokinetic study, or FDA safety signal has documented such an interaction between these agents.

Pharmacodynamic Considerations: Thyroid and Androgen Axes

The thyroid and androgen systems interact indirectly. Hypothyroidism decreases sex hormone-binding globulin (SHBG) production, which can increase free testosterone and alter the ratio of testosterone to dihydrotestosterone (DHT). This is the indirect pathway that occasionally raises questions.

Effect of Thyroid Status on DHT

A 2012 study published in Clinical Endocrinology found that men with subclinical hypothyroidism had lower SHBG levels compared with euthyroid controls. When hypothyroidism is corrected with levothyroxine, SHBG normalizes and free testosterone decreases slightly. This shift is independent of finasteride's mechanism. Finasteride blocks the conversion of testosterone to DHT regardless of thyroid status.

Does Finasteride Affect Thyroid Function?

No. Finasteride has no known effect on TSH, free T4, free T3, or thyroid peroxidase antibodies. The 5-alpha reductase enzyme acts on steroid substrates (testosterone, progesterone, cortisol) but not on thyroid hormones or their transport proteins.

Hair Loss Differential Diagnosis

Both hypothyroidism and androgenetic alopecia cause hair loss, but the patterns differ. Hypothyroid hair loss is typically diffuse, affecting the entire scalp uniformly with changes in hair texture. Androgenetic alopecia follows the Hamilton-Norwood pattern with frontotemporal recession and vertex thinning. Clinicians should confirm euthyroid status (TSH 0.4-4.0 mIU/L) before attributing hair loss solely to androgen sensitivity. The Endocrine Society's clinical practice guidelines recommend TSH screening in any patient presenting with new-onset alopecia.

Timing and Administration Best Practices

Levothyroxine's narrow therapeutic index and absorption sensitivity make timing the most important practical consideration for any co-administered medication.

The 30-60 Minute Rule

The American Thyroid Association recommends taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast or other medications. A 2009 study in Thyroid journal (N=45) demonstrated that taking levothyroxine with coffee reduced absorption by up to 36% in some patients. Apply the same precaution with finasteride: take levothyroxine first, wait at least 30 minutes, then take finasteride with or without food.

Bedtime Dosing Alternative

A randomized crossover trial published in Archives of Internal Medicine (N=90) found that bedtime levothyroxine dosing improved TSH and free T4 levels compared with morning dosing, likely due to longer fasting duration. Patients who prefer bedtime levothyroxine can take finasteride at any other time of day without concern.

Practical Schedule Example

Morning protocol: levothyroxine at 6:00 AM on an empty stomach, finasteride at 6:30 AM or later with breakfast. Bedtime protocol: finasteride with dinner, levothyroxine at bedtime (at least 3 hours after the last meal).

Monitoring Recommendations

No additional monitoring is required specifically for this drug combination. Standard monitoring protocols for each condition apply independently.

Thyroid Monitoring

Check TSH 6-8 weeks after any levothyroxine dose change. Once stable, annual TSH is sufficient for most patients. The target TSH range varies by age and clinical context. The 2014 ATA guidelines suggest maintaining TSH in the lower half of the reference range (0.4-2.5 mIU/L) for most adults under 65.

Finasteride Monitoring

PSA levels decrease by approximately 50% in men taking finasteride 5 mg. The FDA label advises doubling the measured PSA value for accurate prostate cancer screening interpretation. For the 1 mg hair loss dose, PSA reduction averages 30%.

When to Recheck

If a patient on stable levothyroxine starts finasteride and reports new fatigue, cold intolerance, or worsening hair loss, check TSH to rule out thyroid under-replacement. These symptoms overlap between hypothyroidism and are not caused by finasteride, but confirming euthyroid status prevents misattribution.

Drug Interactions That Actually Matter for Levothyroxine

While finasteride is safe to combine, several other medications genuinely reduce levothyroxine efficacy. Awareness of these helps patients contextualize the risk hierarchy.

High-Risk Interactions

Calcium carbonate reduces levothyroxine absorption by 20-25% when taken concurrently, according to a study in Thyroid (N=20). Iron supplements have a similar effect. Proton pump inhibitors (omeprazole, pantoprazole) reduce gastric acidity and impair absorption, sometimes necessitating a 25-50% levothyroxine dose increase according to data from the Journal of Clinical Endocrinology & Metabolism.

Moderate Interactions

Estrogen therapy increases TBG, potentially requiring levothyroxine dose adjustment. Rifampin induces hepatic glucuronidation of T4 and can lower free T4 levels. Carbamazepine and phenytoin both accelerate T4 clearance through enzyme induction.

Low or No Interaction

Finasteride, dutasteride, minoxidil (topical), statins, and most antihypertensives have no meaningful interaction with levothyroxine. Patients taking these combinations can follow standard levothyroxine timing without additional precautions beyond the 30-minute absorption window.

Special Populations

Older Men (Over 65)

Hypothyroidism and BPH frequently co-occur in this group. The 5 mg finasteride dose used for BPH is five times higher than the hair-loss dose. Even at this higher dose, no pharmacokinetic interaction with levothyroxine has been identified in post-marketing surveillance data from the PLESS trial (N=3,040, 4-year follow-up).

Women on Levothyroxine

Finasteride is FDA-approved only for men. Women of childbearing potential should not handle crushed finasteride tablets due to teratogenicity risk (category X). This population concern is unrelated to drug interactions but warrants mention for completeness.

Patients with Hepatic Impairment

Finasteride clearance is reduced in patients with liver disease because CYP3A4 activity decreases. Levothyroxine dosing is unaffected by hepatic impairment because its clearance relies on peripheral deiodination. No dose adjustment for either drug is needed based on the other's presence, though finasteride dose reduction may be needed independently in cirrhosis.

Clinical Bottom Line

The combination of levothyroxine and finasteride is pharmacologically inert from an interaction standpoint. No CYP overlap exists. No absorption interference occurs. No pharmacodynamic antagonism has been demonstrated. Maintain standard levothyroxine timing (empty stomach, 30-60 minutes before other oral medications), monitor TSH on the usual schedule, and counsel patients that both drugs can be taken the same day without special separation beyond the standard absorption window.

Patients experiencing persistent hair loss despite finasteride therapy should have TSH confirmed at 0.4-2.5 mIU/L before concluding treatment failure, as subclinical hypothyroidism contributes independently to diffuse alopecia.